跳至主要内容
临床试验/NCT02856789
NCT02856789已完成不适用

Determination of Fibrin Activity in Plasma on STA-R® Prototype

Diagnostica Stago R&D1 个研究点 分布在 1 个国家目标入组 913 人开始时间: 2016年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
913
试验地点
1
主要终点
Dynamic evolution of fibrin formation

研究概览

简要总结

The purpose of the study is to give the proof of concept of the Fibrin structure assay on STA-R® prototype. It aims to identify the parameters which discriminate the pathologic from the normal population. Secondary objectives are to determine the precision of the assay, to record the Fibrin activity, comparatively with thromboelastography on TEG®, in a coagulation activation assay and in a coagulation-lysis assay.

详细描述

Background. Fibers thickness of the fibrin clot plays an important role on the clot stability and its resistance to the fibrinolysis. The innovative concept, based on the relationship between light spectrum through the fibrin clot and its fiber nanostructure (C.Dassi et al, ISTH 15ABS-3593), thanks to a multi-wavelength STA-R® prototype, was simplified by using a coag-lysis assay (An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: SSC communication ; Pieters et al. ; JTH 2018) Preliminary results suggest that this new automated FS method provides new data on clot analysis and could be a useful tool in clinical practice in the management of hemostasis disorders. This study is extended to begining of march 2019.

Main objective. This study aims to determine the precision, the normal range of the FS method in comparison with Thromboelastography on TEG® and discriminate patients from healthy volunteers (HV).

Recruitment. 200 healthy volunteers without any known coagulation troubles, enrolled during coagulation testing or blood donation.

50 hospitalized patients or patients from consultations, without ongoing treatment (particularly anticoagulant treatment), with a normal hemostasis screening (Prothombin Time, Activated Partial Prothombine Time and Fibrinogen Level).

650 hospitalized patients for any pathology known and able to induce a increase or a decrease of the fibrinogen level, mainly from trauma patients and enrolled during coagulation testing.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients and healthy volunteers with non-opposition to participate in the evaluation
  • Healthy volunteers : from 18 years to 70 years
  • Patients : minimum age limit 18 years - no maximum age limit

排除标准

  • Healthy volonteers with ongoing treatment
  • Healthy volonteers with abnormal hemostasis results

结局指标

主要结局

Dynamic evolution of fibrin formation

时间窗: 12 months

Evolution of the optical density measurement and calculating the fibrinogen level and coagulolytic balance

Dynamic evolution of the number of protofibrils

时间窗: 12 months

Evolution of the Fibrin structure (FS) measurement will be performed on two plasma groups, the first group is constituted with fresh healthy volunteers and the second one with fresh patients. Coagulolytic balance will be measured with FS method. In addition, a normal range will be determined on fresh healthy volunteers without any known coagulation troubles. Fibrin structure is processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.

次要结局

  • Activated Partial Thromboplastin Time (APTT)(12 months)
  • Thrombin Time (TT)(12 months)
  • Prothrombin Time (PT)(12 months)
  • Thromboelastography measurement on TEG 5000(12 months)
  • Fibrinogen(12 months)
  • D-Dimers(12 months)

研究者

发起方
Diagnostica Stago R&D
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验